-
Posted by
Two Blokes Jul 28 -
Filed in
Stock
-
0 views
Toronto, Ontario – TheNewswire - July 28, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received the first purchase order from Lishman Global Inc. for VMS+ technology to be used within its echocardiography image platform in the People's Republic of China. Lishman will use the technology within six hybrid echocardiography systems built to support technology demonstration, clinical validation, and regulatory submission to the China Food and Drug Administration (“CFDA”). Previously, Lishman's Chinese subsidiary had received CFDA approval and a Certificate of Production (CoP) from the CFDA in the People's Republic of China for the VMS+ product used for analysis of the right ventricle (RV) only of the heart. Through the manufacture and sale of a limited number of these systems Lishman was able to develop market insights, validate the market opportunity, identify and engage with channel partners and build market awareness.
